Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430898 · ClinicalTrials.gov registry record · Phase 2
Basiliximab in Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Cerimon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT00430898: Completed Phase 2 study, sponsored by Cerimon Pharmaceuticals.
NCT00430898 is a Phase 2 study that has completed, run by Cerimon Pharmaceuticals. The registered enrollment target is 181 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430898, a Phase 2 study, has completed, sponsored by Cerimon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.
Interventions
- DRUG Basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00430898 record still lists
NCT00430898 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 1 intervention - of which Basiliximab is the first listed.
NCT00430898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00430898 about?
NCT00430898 is a clinical study titled "Basiliximab in Moderate to Severe Ulcerative Colitis". The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.
What is the current status of trial NCT00430898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2007-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00430898?
The interventions under investigation include: Basiliximab (DRUG).
Who is sponsoring clinical trial NCT00430898?
This trial is sponsored by Cerimon Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00430898's enrollment target sits among peer trials
181 365th of 2000 higher than 1,636 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia